Leber congenital amaurosis (LCA) is a blinding retinal disease that presents within the first year after birth. Using exome sequencing, we identified mutations in the nicotinamide adenine dinucleotide (NAD) synthase gene NMNAT1 encoding nicotinamide mononucleotide adenylyltransferase 1 in eight families with LCA, including the family in which LCA was originally linked to the LCA9 locus. Notably, all individuals with NMNAT1 mutations also have macular colobomas, which are severe degenerative entities of the central retina (fovea) devoid of tissue and photoreceptors. Functional assays of the proteins encoded by the mutant alleles identified in our study showed that the mutations reduce the enzymatic activity of NMNAT1 in NAD biosynthesis and affect protein folding. Of note, recent characterization of the slow Wallerian degeneration (Wld s ) mouse model, in which prolonged axonal survival after injury is observed, identified NMNAT1 as a neuroprotective protein when ectopically expressed. Our findings identify a new disease mechanism underlying LCA and provide the first link between endogenous NMNAT1 dysfunction and a human nervous system disorder.
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The molecular mechanisms underlying neurodegeneration are highly complex, and strategies to prevent this process are under intense investigation 1, 2 . Important insights into protection from neurodegeneration come from studies of the Wld s mouse model, which harbors a spontaneous mutation and has a marked reduction in the rate of axonal degeneration after injury [3] [4] [5] [6] [7] . This protective effect is due to the expression of a unique chimeric protein, named the Wld s fusion protein, that is composed of ubiquitination factor E4B (Ube4b) and full-length Nmnat1 (refs. 8,9), a highly conserved protein that is present throughout evolution from archaebacteria to humans. Recent work has shown that the Nmnat1 portion of the Wld s fusion protein is responsible for the observed delay in axonal degeneration 10 . NMNAT1 is an essential enzyme in NAD biosynthesis. Despite the intense interest in and importance of NMNAT1, the mechanism by which NMNAT1 protects against neurodegeneration remains controversial. Although the enzymatic activity does not seem to be necessary for neuroprotection in Drosophila melanogaster 11 , both NAD synthase domain activity and the presence of other domains are needed in vertebrates for the neuroprotective function of NMNAT1 (ref. 12 ). In addition, little is known about the endogenous function of NMNAT1 in neuronal cells in vertebrates. Nmnat1 mutation resulting in complete loss of function in mice results in embryonic lethality, whereas heterozygous loss of Nmnat1 does not cause acceleration of neurodegeneration after injury 13 . To date, no mutations in NMNAT1 have been associated with any human disease. Here, we report that biallelic NMNAT1 mutations cause LCA, a severe neurodegenerative condition of the retina, which is the most active metabolic tissue of the human body 14 .
Early-onset neurodegeneration in the human retina can lead to LCA (MIM 204000), the most severe human form of inherited photoreceptor-neuron degeneration resulting in congenital blindness, with an incidence of ~1 in 80,000 (ref. 15) . LCA is genetically and clinically heterogeneous, with mutations in 16 genes implicated Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration 1 0 3 6 VOLUME 44 | NUMBER 9 | SEPTEMBER 2012 Nature GeNetics l e t t e r s so far in the disease, explaining 70% of cases. The proteins encoded by these genes are involved in a range of functions, including ciliary transport, phototransduction, retinoid cycling and photoreceptor development [15] [16] [17] . To identify new LCA-associated genes underlying the remaining 30% of unresolved LCA cases, we performed wholeexome sequencing experiments. We first screened individuals with LCA for mutations in all known LCA-associated genes using APEX technology (Asper Ophthalmics) and Sanger sequencing. We then captured the exomes of the first 50 individuals with LCA who lacked mutations in known LCA-causing genes as described 18 . Nextgeneration sequencing of these samples identified three unrelated individuals with LCA (MOGL208, MOGL512 and MOGL1269) with compound heterozygous variants in NMNAT1 (NM_022787). All three of these individuals have the same p.Glu257Lys missense variant ( Table 1) . Additionally, subject MOGL208 carries the missense variant p.Asn273Asp, subject MOGL512 carries the missense variant p.Arg207Trp and subject MOGL1269 carries the missense variant p.Val151Phe. Cosegregation of the alleles encoding these variants in the pedigrees ( Fig. 1 ) and the absence of these mutations in 200 normal controls indicate that NMNAT1 is likely to be a new LCA-causing gene. To confirm this finding, we sequenced the coding region of NMNAT1 in 150 additional individuals with LCA. Another four affected individuals were found to carry either compound heterozygous or homozygous mutations in NMNAT1 ( Fig. 1 and Table 1) . Notably, NMNAT1 maps to 1p36 within the LCA9 locus that was first identified through linkage analysis in a large consanguineous Pakistani family with LCA, making it an excellent candidate gene. Indeed, in a parallel sequencing experiment, we identified a homozygous NMNAT1 mutation (encoding p.*280Gln) that segregated perfectly with the disease in the original family in which LCA9 was identified 19 (Fig. 1) . Thus, in total, we identified ten mutant alleles of NMNAT1 in eight families with LCA, including a nonsense mutation (encoding p.Trp169*), a read-through mutation (encoding p.*280Gln) and eight missense mutations that are likely to cause partial loss of function ( Supplementary Fig. 1a ,b and Supplementary Table 1) . We validated all mutant alleles by direct PCR Sanger sequencing (Supplementary Fig. 2 ).
Because NMNAT1 is ubiquitously expressed, we re-examined the phenotype of all individuals with NMNAT1 mutations and interviewed children and parents about their general health. All individuals with biallelic NMNAT1 mutations had severe LCA but normal physical and mental health. Notably, in addition to the typical LCA phenotype of nystagmus, severe loss of vision and abnormal electroretinogram (ERG), all individuals with biallelic NMNAT1 mutations were found to have a peculiar, prominent retinal feature termed 'macular coloboma' , which consists of an atrophic lesion in the central retina with a pigmented border, signifying complete loss of neural tissue in the fovea, including of photoreceptors, bipolar cells and ganglion cells (Fig. 2) . This suggests that NMNAT1 mutations are associated with severe and rapid foveal degeneration. The rest of the retina was abnormal as well, with pigmentary changes, attenuated retinal blood vessels and optic disc pallor. In addition, other layers of the retina, such as the ganglion cell layer, were also severely affected (Fig. 2) . 
l e t t e r s
Some infants with macular colobomas are misdiagnosed with parasitic Toxoplasma retinal infection, which has a similar presentation but a very different etiology and prognosis.
On the basis of our observation that five families carried the p.Glu257Lys variant, we tested whether the allele encoding this variant represents a founder mutation. Genotyping of surrounding SNPs and haplotype analysis confirmed that all individuals of European descent carrying the mutation encoding p.Glu257Lys share the same haplotype, strongly suggesting that this is a founder mutation (Supplementary Fig. 3 ). On the basis of this finding, we developed an amplification-refractory mutation system (ARMS) primer set that easily distinguishes between the wild-type and mutant alleles in one PCR reaction to facilitate rapid and inexpensive molecular diagnosis for newborns with LCA carrying NMNAT1 mutations and those with macular colobomas (Supplementary Fig. 1c) .
Close examination of the position of altered residues in the NMNAT1 crystal structure suggests that its structure and function are likely to be affected by the mutations (Supplementary Fig. 1b) . For example, two charged residues, Arg207 and Glu257, are located at a protein-interaction domain interface that has an important role during hexamerization of the enzyme. Substituting a hydrophobic tryptophan for a positively charged arginine (p.Arg207Trp) or a positively charged lysine for a negatively charged glutamic acid (p.Glu257Lys) is likely to directly interfere with hexamer formation. In addition, the Asn273 residue is in close proximity to the pyridine-binding site and is thought to be involved in the coordination of an active site water molecule and to have a role in substrate recognition (Fig. 1b  and Supplementary Fig. 1b) 20 . Therefore, these missense mutations may negatively affect the function of the protein rather than altering NMNAT1 expression. Indeed, mutant alleles of NMNAT1 are expressed in subjects MOGL208 and MOGL512 (Supplementary Fig. 4) .
On the basis of these in silico predictions, we performed both in vivo and in vitro functional assays. We first assessed whether enzymatic function in NAD biosynthesis was negatively affected in vivo in red blood cells (RBCs) from an individual with LCA and his heterozygous mother. We obtained fresh RBCs from the MOGL624 family and measured the level of NAD production. We observed significantly lower concentrations of NAD in the affected individual, who is homozygous for the mutation encoding the p.Glu257Lys variant, compared to his heterozygous mother, suggesting reduced enzymatic function of the mutant NMNAT1 protein (Fig. 3a) . To further examine the impact of these mutations on enzymatic activity, we performed in vitro assays using affinity-purified wild-type and mutant NMNAT1 proteins. Consistent with the in vivo findings, NMNAT1 proteins with p.Val151Phe, p.Arg207Trp, p. Glu257Lys and p.Asn273Asp alterations also had significantly reduced enzymatic activity compared to the wild-type protein in the in vitro assays (Fig. 3b) . In parallel, we engineered the most common mutation found in our study (encoding p.Glu257Lys) into NMNAT1 cDNA. We transfected HeLa cells with the constructs encoding either wild-type or mutant protein and then examined protein expression by immunohistochemistry. Consistent with previous studies, we observed strong nuclear staining of NMNAT1 in cells transfected with the wild-type construct (Fig. 3c) . Conversely, we observed strong staining of NMNAT1 p.Glu257Lys outside the cell nucleus in the cytoplasm (Fig. 3c) . The mutant NMNAT1 was likely aggregated in the cytoplasm, as it was insoluble, and was positive for ubiquitin staining, indicating that the p.Glu257Lys substitution likely affects proper protein folding (Fig. 3c,d) .
In summary, we have identified NMNAT1 as the disease-causing gene at the LCA9 locus and have provided the first link between a human nervous system disease and endogenous NMNAT1 function. npg l e t t e r s
As has been shown in Drosophila, human NMNAT1 seems to be an essential protein for photoreceptor neuron function and survival; however, the underlying mechanisms may be distinct 6, 11, 12, [21] [22] [23] . Consistent with the idea that the protective effects of NMNAT1 are correlated with NAD production in the vertebrate model, our results suggest that LCA-causing NMNAT1 mutations reduce enzyme activity and lower NAD levels in affected individuals. However, as the molecular mechanisms of NMNAT1 in neuroprotection remain controversial and the intrinsic differences between the peripheral and central nervous systems are not yet fully understood, it is possible that mechanisms other than alterations in NAD production account for the retinal phenotypes observed in individuals with NMNAT1 mutations. Finally, it is worth noting that, as NAD supplementation has been shown to significantly delay axonal degeneration in the mouse after injury 10 , our work raises the possibility that increasing NAD levels in the retinas of individuals with LCA with NMNAT1 mutations may be a potential therapeutic option. Figure 3 Functional assays of mutant NMNAT1 proteins. (a) Total NAD levels in fresh RBCs from an affected individual homozygous for the mutation encoding p.Glu257Lys and his heterozygous mother. NAD is present at significantly lower levels in the affected proband compared with his carrier mother (****P < 0.0001 
